8 results on '"Nobili, Valerio"'
Search Results
2. Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future?
- Author
-
Hatton, Grace, Alterio, Tommaso, Nobili, Valerio, Mann, Jake P, Mann, Jake [0000-0002-4711-9215], and Apollo - University of Cambridge Repository
- Subjects
Metabolic Syndrome ,Biomedical Research ,pediatrics ,Adolescent ,Host Microbial Interactions ,Infant, Newborn ,nutritional and metabolic diseases ,microbiome ,Infant ,Risk Assessment ,digestive system diseases ,Gastrointestinal Microbiome ,Cardiovascular Diseases ,Non-alcoholic Fatty Liver Disease ,hepatology ,Child, Preschool ,Nonalcoholic fatty liver disease ,fatty liver disease ,Dysbiosis ,Humans ,Child - Abstract
Pediatric nonalcoholic fatty liver disease (NAFLD) is common disorder that has complex pathophysiology and unquantified clinical significance. Though there have been major advances in the field, there is much yet to be understood. Areas covered: PubMed/MEDLINE and Embase were searched for articles related to pediatric NAFLD and nonalcoholic steatohepatitis (NASH) between January 1998 and January 2018. The areas considered to be 'unmet needs' were the relationship between the intestinal microbiome and perinatal events, clinical event risk stratification, and mechanisms underlying portal inflammation. Expert commentary: In utero and ex utero factors have been associated with NAFLD and also with the intestinal microbiome, but it is not yet known how intestinal dysbiosis can be reversed and whether intervention in high-risk neonates could alter their propensity for the metabolic syndrome. Children with NAFLD are at increased risk of cardiovascular, diabetic, and hepatic diseases, but it is unclear how best to stratify children into appropriate risk groups for targeted interventions. Finally, the immune processes underlying pediatric NASH are thought to differ to those in adult NASH, yet the events surrounding activation of periportal lymphocytes are poorly understood. Deepening our understanding of these topics may lead to novel therapeutic targets.
- Published
- 2018
- Full Text
- View/download PDF
3. Additional file 1: of Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics
- Author
-
Valerio, Giuliana, Maffeis, Claudio, Saggese, Giuseppe, Ambruzzi, Maria, Balsamo, Antonio, Bellone, Simonetta, Bergamini, Marcello, Bernasconi, Sergio, Bona, Gianni, Calcaterra, Valeria, Canali, Teresa, Caroli, Margherita, Chiarelli, Francesco, Corciulo, Nicola, Crinò, Antonino, Procolo Di Bonito, Pietrantonio, Violetta Di, Pietro, Mario Di, Sessa, Anna Di, Diamanti, Antonella, Doria, Mattia, Fintini, Danilo, Franceschi, Roberto, Franzese, Adriana, Giussani, Marco, Grugni, Graziano, Iafusco, Dario, Iughetti, Lorenzo, Adima Lamborghini, Licenziati, Maria, Limauro, Raffaele, Maltoni, Giulio, Manco, Melania, Reggiani, Leonardo, Marcovecchio, Loredana, Marsciani, Alberto, Giudice, Emanuele Del, Morandi, Anita, Morino, Giuseppe, Moro, Beatrice, Nobili, Valerio, Perrone, Laura, Picca, Marina, Pietrobelli, Angelo, Privitera, Francesco, Purromuto, Salvatore, Ragusa, Letizia, Ricotti, Roberta, Santamaria, Francesca, Sartori, Chiara, Stilli, Stefano, Street, Maria, Tanas, Rita, Trifiró, Giuliana, Umano, Giuseppina, Vania, Andrea, Verduci, Elvira, and Zito, Eugenio
- Abstract
Level of evidence and grade of recommendations according to the National Guidelines System [4]. (DOCX 15Â kb)
- Published
- 2018
- Full Text
- View/download PDF
4. Nonalcoholic fatty liver disease
- Author
-
Brunt, Elizabeth M, Wong, Vincent W-S, Nobili, Valerio, Day, Christopher P, Sookoian, Silvia, Maher, Jacquelyn J, Bugianesi, Elisabetta, Sirlin, Claude B, Neuschwander-Tetri, Brent A, and Rinella, Mary E
- Subjects
Liver Cirrhosis ,Liver Disease ,Prevention ,Carcinoma ,Liver Neoplasms ,Chronic Liver Disease and Cirrhosis ,Clinical Sciences ,Hepatocellular ,Metabolic and Endocrine ,digestive system diseases ,Hepatitis ,Rare Diseases ,Oral and Gastrointestinal ,Liver ,Non-alcoholic Fatty Liver Disease ,Clinical Research ,Hepatocytes ,Disease Progression ,Humans ,2.1 Biological and endogenous factors ,Obesity ,Insulin Resistance ,Digestive Diseases ,Nutrition - Abstract
Nonalcoholic fatty liver disease (NAFLD) is a disorder characterized by excess accumulation of fat in hepatocytes (nonalcoholic fatty liver (NAFL)); in up to 40% of individuals, there are additional findings of portal and lobular inflammation and hepatocyte injury (which characterize nonalcoholic steatohepatitis (NASH)). A subset of patients will develop progressive fibrosis, which can progress to cirrhosis. Hepatocellular carcinoma and cardiovascular complications are life-threatening co-morbidities of both NAFL and NASH. NAFLD is closely associated with insulin resistance; obesity and metabolic syndrome are common underlying factors. As a consequence, the prevalence of NAFLD is estimated to be 10-40% in adults worldwide, and it is the most common liver disease in children and adolescents in developed countries. Mechanistic insights into fat accumulation, subsequent hepatocyte injury, the role of the immune system and fibrosis as well as the role of the gut microbiota are unfolding. Furthermore, genetic and epigenetic factors might explain the considerable interindividual variation in disease phenotype, severity and progression. To date, no effective medical interventions exist that completely reverse the disease other than lifestyle changes, dietary alterations and, possibly, bariatric surgery. However, several strategies that target pathophysiological processes such as an oversupply of fatty acids to the liver, cell injury and inflammation are currently under investigation. Diagnosis of NAFLD can be established by imaging, but detection of the lesions of NASH still depend on the gold-standard but invasive liver biopsy. Several non-invasive strategies are being evaluated to replace or complement biopsies, especially for follow-up monitoring.
- Published
- 2015
5. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ
- Author
-
Povero, Davide, Panera, Nadia, Eguchi, Akiko, Johnson, Casey D, Papouchado, Bettina G, de Araujo Horcel, Lucas, Pinatel, Eva M, Alisi, Anna, Nobili, Valerio, and Feldstein, Ariel E
- Subjects
Extracellular Vesicles ,miRNAs ,Liver Fibrosis ,Hepatic Stellate Cell ,Lipotoxicity - Abstract
Background&aimsHepatic stellate cells (HSCs) play a key role in liver fibrosis in various chronic liver disorders including nonalcoholic fatty liver disease (NAFLD). The development of liver fibrosis requires a phenotypic switch from quiescent to activated HSCs. The triggers for HSCs activation in NAFLD remain poorly understood. We investigated the role and molecular mechanism of extracellular vesicles (EVs) released by hepatocytes during lipotoxicity in modulation of HSC phenotype.MethodsEVs were isolated from fat-laden hepatocytes by differential centrifugation and incubated with HSCs. EV internalization and HSCs activation, migration and proliferation were assessed. Loss- and gain-of-functions studies were performed to explore the potential role of PPAR-γ-targeting miRNAs carried by EVs into HSC.ResultsHepatocyte-derived EVs released during lipotoxicity are efficiently internalized by HSCs resulting in their activation, as shown by marked up-regulation of pro-fibrogenic genes (Collagen-I, α-SMA and TIMP-2), proliferation, chemotaxis and wound healing responses. These changes were associated with miRNAs shuttled by EVs and suppression of PPAR-γ expression in HSC. Hepatocyte-derived EVs miRNA content included various miRNAs that are known inhibitors of PPAR-γ expression with miR-128-3p being the most effectively transferred. Furthermore loss- and gain-of-function studies identified miR-128-3p as a central modulator of the effects of EVs on PPAR-γ inhibition and HSC activation.ConclusionOur findings demonstrate a link between fat-laden hepatocyte-derived EVs and liver fibrosis and have potential implications for the development of novel anti-fibrotic targets for NAFLD and other fibrotic diseases.
- Published
- 2015
6. Metabolic syndrome
- Author
-
Corte, Claudia Della, Alterio, Arianna, and Nobili, Valerio
- Subjects
Meeting Abstract - Published
- 2015
7. PRO- AND ANTI-OXIDANTS MODULATE THE BALANCE BETWEEN APOPTOSIS AND PROLIFERATION IN HEPATOMA CELLS BY REGULATING NF-kappa B GLUTATHIONYLATION
- Author
-
Alisi, Anna, Piemonte, Fiorella, Gaeta, Laura Maria, Passarelli, Chiara, Tozzi, Giulia, Stefania Petrini, Marcellini, Matilde, Bottazzo, Gian Franco, and Nobili, Valerio
8. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
- Author
-
Valerio Nobili, Roberto Vettor, Giulio Marchesini, Hannele Yki-Järvinen, Herbert Tilg, Christopher P. Day, Gema Frühbeck, Lisbeth Mathus-Vliegen, Jean-François Dufour, Vlad Ratziu, Amalia Gastaldelli, Ali Canbay, Fritz Schick, Michael Roden, MARCHESINI REGGIANI, Giulio, Day, Christopher P., Dufour, Jean Françoi, Canbay, Ali, Nobili, Valerio, Ratziu, Vlad, Tilg, Herbert, Roden, Michael, Gastaldelli, Amalia, Yki Järvinen, Hannele, Schick, Fritz, Vettor, Roberto, Frühbeck, Gema, Mathus Vliegen, Lisbeth, Dufour, Jean Francoi, Yki Jarvinen, Hannele, and Fruhbeck, Gema
- Subjects
medicine.medical_specialty ,Health (social science) ,Disease ,03 medical and health sciences ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Physiology (medical) ,medicine ,Humans ,Algorithms ,Liver ,Hepatology ,business.industry ,Fatty liver ,Elafibranor ,Non alcoholic ,medicine.disease ,Clinical Practice ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Clinical Practice Guidelines ,business ,TM6SF2 - Abstract
The Clinical Practice Guidelines (CPG) propose recommendations for the diagnosis, treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the product of a joint effort by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). They update a position statement based on the 2009 EASL Special Conference [1] .The data have been retrieved by an extensive PubMed search up to April 2015. The final statements are graded according to the level of evidence and strength of recommendation, which are adjustable to local regulations and/or team capacities ( table 1 ) [2] . In particular, screening for NAFLD in the population at risk should be in the context of the available resources, considering the burden for the national healthcare systems and the currently limited effective treatments. The document is intended both for practical use and for advancing the research and knowledge of NAFLD in adults, with specific reference to paediatric NAFLD, whenever necessary. The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.